{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T02:09:24Z","timestamp":1761962964485,"version":"3.41.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T00:00:00Z","timestamp":1734998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006662","name":"NIHR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006662","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To update the first-line conventional synthetic DMARDs (csDMARDs) prescribing pattern, describe change and variation across demographical and geographical factors in the RA population, and identify individual and hospital factors associated with it.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This retrospective cohort study included newly diagnosed RA adult patients from 1 May 2018 to 1 April 2023 in the UK. We used adjusted multinomial logistic regression with random effect to explore associations with different first-line csDMRAD prescription and to account for hospital-level clustering.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We identified 15\u2009462 RA patients who received csDMARD treatment. Overall, 57% received MTX monotherapy and 14% received MTX combination therapy as first-line treatment. MTX is the most frequently medication, following by HCQ and SSZ. Compared with non-MTX prescription, prescription of MTX monotherapy [adjusted odds ratio (aOR) 1.25 95% CI (1.22\u20131.29)] and MTX combination therapy [aOR 1.45 (1.38\u20131.52)] was significantly higher in patients with higher DAS28, but lower in the non-White individuals with comorbidities: lung disease, cancer, fracture and heart attack. Among those who received MTX, monotherapy is more likely be prescribed in patients with higher DAS28 [aOR 1.08 (1.05\u20131.11)] and without lung disease [aOR 0.5 (0.44\u20130.56)], compared with combination therapy. Around 20% of the variability in first-line csDMARD prescribing was attributed to the hospital level.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In this cohort study of new-onset RA population, both individual- and institution-level variation in first-line csDMARD treatment strategy was evident. Gender, ethnicity, disease activity, and comorbidities, especially lung disease, were associated with disparities at the individual level.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keae717","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T20:34:34Z","timestamp":1734640474000},"page":"3379-3387","source":"Crossref","is-referenced-by-count":1,"title":["Association of patient- and hospital-level predictors with patterns of initial treatment in patients with rheumatoid arthritis: findings from a national cohort study"],"prefix":"10.1093","volume":"64","author":[{"given":"Zijing","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Inflammation Biology, Centre for Rheumatic Diseases, King\u2019s College London , London,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Alveyn","sequence":"additional","affiliation":[{"name":"Department of Inflammation Biology, Centre for Rheumatic Diseases, King\u2019s College London , London,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8171-7772","authenticated-orcid":false,"given":"Mark","family":"Russell","sequence":"additional","affiliation":[{"name":"Department of Inflammation Biology, Centre for Rheumatic Diseases, King\u2019s College London , London,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie","family":"Bechman","sequence":"additional","affiliation":[{"name":"Department of Inflammation Biology, Centre for Rheumatic Diseases, King\u2019s College London , London,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Callum","family":"Coalwood","sequence":"additional","affiliation":[{"name":"British Society for Rheumatology, Bride House , London,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3042-0201","authenticated-orcid":false,"given":"Elizabeth","family":"Price","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Great Western Hospital NHS Foundation Trust , Swindon,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0121-4919","authenticated-orcid":false,"given":"Abhishek","family":"Abhishek","sequence":"additional","affiliation":[{"name":"The University of Nottingham, Nottingham NIHR-BRC , Nottingham,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1714-9963","authenticated-orcid":false,"given":"Sam","family":"Norton","sequence":"additional","affiliation":[{"name":"Department of Inflammation Biology, Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, Centre for Rheumatic Diseases, King\u2019s College London , London,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1230-2781","authenticated-orcid":false,"given":"James","family":"Galloway","sequence":"additional","affiliation":[{"name":"Department of Inflammation Biology, Centre for Rheumatic Diseases, King\u2019s College London , London,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,12,24]]},"reference":[{"key":"2025052703531990700_keae717-B1","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1002\/1529-0131(200112)44:12<2746::AID-ART461>3.0.CO;2-Z","article-title":"Long-term morbidity, mortality, and economics of rheumatoid arthritis","volume":"44","author":"Wong","year":"2001","journal-title":"Arthritis Rheum"},{"key":"2025052703531990700_keae717-B2","doi-asserted-by":"crossref","first-page":"e594","DOI":"10.1016\/S2665-9913(23)00211-4","article-title":"Global, regional, and national burden of rheumatoid arthritis, 1990\u20132020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021","volume":"5","author":"Black","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"2025052703531990700_keae717-B3","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/art.22353","article-title":"Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: a meta-analysis","volume":"55","author":"Finckh","year":"2006","journal-title":"Arthritis Care Res"},{"key":"2025052703531990700_keae717-B4","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1093\/rheumatology\/keh199","article-title":"Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis","volume":"43","author":"Nell","year":"2004","journal-title":"Rheumatology"},{"key":"2025052703531990700_keae717-B5","doi-asserted-by":"crossref","first-page":"e332","DOI":"10.1016\/S2665-9913(20)30061-8","article-title":"Referring early arthritis patients within 6 weeks versus 12 weeks after symptom onset: an observational cohort study","volume":"2","author":"Niemantsverdriet","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"2025052703531990700_keae717-B6","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"2025052703531990700_keae717-B7","doi-asserted-by":"crossref","first-page":"m4328","DOI":"10.1136\/bmj.m4328","article-title":"Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial","volume":"371","author":"Hetland","year":"2020","journal-title":"BMJ"},{"key":"2025052703531990700_keae717-B8","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s40801-024-00416-3","article-title":"Disease-modifying medications in patients with rheumatoid arthritis in the USA: trends from 2016 to 2021","volume":"18","author":"Peasah","year":"2024","journal-title":"Drugs Real World Outcomes"},{"key":"2025052703531990700_keae717-B9","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/art.41752","article-title":"2021 American college of rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2025052703531990700_keae717-B10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Josef","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025052703531990700_keae717-B11","doi-asserted-by":"crossref","first-page":"e2335950","DOI":"10.1001\/jamanetworkopen.2023.35950","article-title":"Monotreatment with conventional antirheumatic drugs or glucocorticoids in rheumatoid arthritis: a network meta-analysis","volume":"6","author":"Guski","year":"2023","journal-title":"JAMA Network Open"},{"key":"2025052703531990700_keae717-B12","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0140-6736(22)01193-X","article-title":"Intervention with methotrexate in patients with arthralgia at risk of rheumatoid arthritis to reduce the development of persistent arthritis and its disease burden (TREAT EARLIER): a randomised, double-blind, placebo-controlled, proof-of-concept trial","volume":"400","author":"Krijbolder","year":"2022","journal-title":"The Lancet"},{"key":"2025052703531990700_keae717-B13","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2025052703531990700_keae717-B14","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/art.23721","article-title":"American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis","volume":"59","author":"Saag","year":"2008","journal-title":"Arthritis Care Res"},{"year":"2009","author":"Rheumatoid arthritis in adults: management: National Institute for Health and Care Excellece","key":"2025052703531990700_keae717-B15"},{"key":"2025052703531990700_keae717-B16","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/acr.23759","article-title":"Low persistence rates in patients with rheumatoid arthritis treated with triple therapy and adverse drug events associated with sulfasalazine","volume":"71","author":"Erhardt","year":"2019","journal-title":"Arthritis Care Res"},{"key":"2025052703531990700_keae717-B17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025052703531990700_keae717-B18","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1136\/annrheumdis-2016-209212","article-title":"Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-label superiority trial","volume":"76","author":"Patrick","year":"2017","journal-title":"Annals of the Rheumatic Diseases"},{"key":"2025052703531990700_keae717-B19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis & Rheumatology"},{"key":"2025052703531990700_keae717-B20","doi-asserted-by":"crossref","first-page":"e028466","DOI":"10.1136\/bmjopen-2018-028466","article-title":"Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts","volume":"9","author":"Kiely","year":"2019","journal-title":"BMJ Open"},{"key":"2025052703531990700_keae717-B21","doi-asserted-by":"crossref","first-page":"2000337","DOI":"10.1183\/13993003.00337-2020","article-title":"Methotrexate and rheumatoid arthritis associated interstitial lung disease","volume":"57","author":"Juge","year":"2021","journal-title":"Eur Respir J"},{"key":"2025052703531990700_keae717-B22","doi-asserted-by":"crossref","first-page":"e001603","DOI":"10.1136\/bmjopen-2012-001603","article-title":"Regional and temporal variation in the treatment of rheumatoid arthritis across the UK: a descriptive register-based cohort study","volume":"2","author":"Christopher John","year":"2012","journal-title":"BMJ Open"},{"key":"2025052703531990700_keae717-B23","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.clinthera.2011.12.016","article-title":"Factors associated with the initiation of disease-modifying antirheumatic drugs in newly diagnosed rheumatoid arthritis: a retrospective claims database study","volume":"34","author":"Bonafede","year":"2012","journal-title":"Clin Ther"},{"key":"2025052703531990700_keae717-B24","doi-asserted-by":"crossref","first-page":"5679","DOI":"10.3390\/ijerph18115679","article-title":"Treatment patterns and pharmacoutilization in patients affected by rheumatoid arthritis in Italian settings","volume":"18","author":"Perrone","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"2025052703531990700_keae717-B25","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00296-018-3933-4","article-title":"Variability in the prescription of biological drugs in rheumatoid arthritis in Spain: a multilevel analysis","volume":"38","author":"L\u00f3pez-Longo","year":"2018","journal-title":"Rheumatology International"},{"key":"2025052703531990700_keae717-B26","doi-asserted-by":"crossref","first-page":"934","DOI":"10.3899\/jrheum.080762","article-title":"The gap between practice and guidelines in the choice of first-line disease modifying antirheumatic drug in early rheumatoid arthritis: results from the ESPOIR cohort","volume":"36","author":"Benhamou","year":"2009","journal-title":"J Rheumatol"},{"key":"2025052703531990700_keae717-B27","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1093\/rheumatology\/keh297","article-title":"Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria","volume":"43","author":"Fransen","year":"2004","journal-title":"Rheumatology"},{"key":"2025052703531990700_keae717-B28","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/00220973.2014.952397","article-title":"Alternatives to multilevel modeling for the analysis of clustered data","volume":"84","author":"Huang","year":"2016","journal-title":"The Journal of Experimental Education"},{"key":"2025052703531990700_keae717-B29","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1136\/jech.2004.029454","article-title":"A brief conceptual tutorial of multilevel analysis in social epidemiology: using measures of clustering in multilevel logistic regression to investigate contextual phenomena","volume":"60","author":"Merlo","year":"2006","journal-title":"J Epidemiol Community Health"},{"key":"2025052703531990700_keae717-B30","first-page":"1032","article-title":"Identifying and quantifying variation between healthcare organisations and geographical regions: using mixed-effects models","volume":"28","author":"Abel","year":"2019","journal-title":"BMJ Qual Saf"},{"key":"2025052703531990700_keae717-B31","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1002\/sim.7336","article-title":"Intermediate and advanced topics in multilevel logistic regression analysis","volume":"36","author":"Austin","year":"2017","journal-title":"Statistics in Medicine"},{"key":"2025052703531990700_keae717-B32","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1146\/annurev.psych.58.110405.085530","article-title":"Missing data analysis: making it work in the real world","volume":"60","author":"Graham","year":"2009","journal-title":"Annu Rev Psychol"},{"key":"2025052703531990700_keae717-B33","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1093\/ije\/dyz032","article-title":"Accounting for missing data in statistical analyses: multiple imputation is not always the answer","volume":"48","author":"Hughes","year":"2019","journal-title":"Int J Epidemiol"},{"key":"2025052703531990700_keae717-B34","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1001\/jamasurg.2021.0528","article-title":"STROBE reporting guidelines for observational studies","volume":"156","author":"Ghaferi","year":"2021","journal-title":"JAMA Surg"},{"key":"2025052703531990700_keae717-B35","doi-asserted-by":"crossref","first-page":"e002700","DOI":"10.1136\/rmdopen-2022-002700","article-title":"Comorbidities and treatment patterns in early rheumatoid arthritis: a nationwide Swedish study","volume":"8","author":"Tidblad","year":"2022","journal-title":"RMD Open"},{"key":"2025052703531990700_keae717-B36","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1007\/s00296-018-4161-7","article-title":"Patterns of the initiation of disease-modifying antirheumatic drugs in incident rheumatoid arthritis: a German perspective based on nationwide ambulatory drug prescription data","volume":"38","author":"Steffen","year":"2018","journal-title":"Rheumatol Int"},{"key":"2025052703531990700_keae717-B37","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/annrheumdis-2015-208840","article-title":"The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation","volume":"75","author":"G\u00f6testam Skorpen","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2025052703531990700_keae717-B38","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/art.22890","article-title":"Treatment of older adult patients diagnosed with rheumatoid arthritis: improved but not optimal","volume":"57","author":"Schmajuk","year":"2007","journal-title":"Arthritis Care Res"},{"key":"2025052703531990700_keae717-B39","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/art.21077","article-title":"Gaps in care for rheumatoid arthritis: a population study","volume":"53","author":"Lacaille","year":"2005","journal-title":"Arthritis Care Res"},{"key":"2025052703531990700_keae717-B40","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/acr.21900","article-title":"Incidence of rheumatoid arthritis in Sweden: a nationwide population-based assessment of incidence, its determinants, and treatment penetration","volume":"65","author":"Eriksson","year":"2013","journal-title":"Arthritis Care Res"},{"key":"2025052703531990700_keae717-B41","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1186\/s13075-015-0895-8","article-title":"Half of U.K. patients with rheumatoid arthritis are prescribed oral glucocorticoid therapy in primary care: a retrospective drug utilisation study","volume":"17","author":"Black","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2025052703531990700_keae717-B42","doi-asserted-by":"crossref","first-page":"e1917053","DOI":"10.1001\/jamanetworkopen.2019.17053","article-title":"Association of patient, prescriber, and region with the initiation of first prescription of biologic disease-modifying antirheumatic drug among older patients with rheumatoid arthritis and identical health insurance coverage","volume":"2","author":"Tatangelo","year":"2019","journal-title":"JAMA Network Open"},{"key":"2025052703531990700_keae717-B43","doi-asserted-by":"crossref","first-page":"rkae053","DOI":"10.1093\/rap\/rkae053","article-title":"Trust performance in managing inflammatory arthritis over time in England and Wales: a latent class analysis approach","volume":"8","author":"Yang","year":"2024","journal-title":"Rheumatol Adv Pract"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae717\/61272016\/keae717.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/6\/3379\/61272016\/keae717.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/6\/3379\/61272016\/keae717.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T07:53:35Z","timestamp":1748332415000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/6\/3379\/7932134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,24]]},"references-count":43,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,12,24]]},"published-print":{"date-parts":[[2025,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae717","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"type":"print","value":"1462-0324"},{"type":"electronic","value":"1462-0332"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2024,12,24]]}}}